6- Abruzzese E, Trawinska MM, Perrotti AP, De Fabritiis P. Tyrosine kinase inhibitors and pregnancy.
Mediterr J Hematol Infect Dis. 2014 Apr 7;6(1):e2014028. doi: 10.4084/MJHID.2014.028. eCollection
2014. Review. PubMed PMID: 24804001
7- Pye SM, Cortes J, Ault P, Hatfield A, Kantarjian H, Pilot R et al. The effects of imatinib on pregnancy
outcome. Blood. 2008 Jun 15;111(12):5505-8. doi: 10.1182/blood-2007-10-114900. Epub 2008 Mar 5.
8- Abruzzese E, Mauro M, Apperley J, Chelysheva E. Tyrosine kinase inhibitors and pregnancy in chronic
myeloid leukemia: opinion, evidence, and recommendations. Ther Adv Hematol. 2020 Oct
31;11:2040620720966120.
9- Cortes JE, Abruzzese E, Chelysheva E, et al. The impact of dasatinib on pregnancy outcomes. Am J
Hematol 2015; 90: 1111–1115.
10- Abruzzese E, Trawinska MM, de Fabritiis P, Baccarani M. Management of pregnant chronic
myeloid leukemia patients. Expert Rev Hematol. 2016 Aug;9(8):781-91. doi:
10.1080/17474086.2016.1205479. Epub 2016 Jul 7. Review. PMID: 27352939
11- Hehlmann R. The New ELN Recommendations for Treating CML. J Clin Med. 2020 Nov
16;9(11):3671.
SCIENTIFIC PROGRAMME
SESSION I
OPTIMIZING
CYTOREDUCTION
SESSION II
MANAGEMENT OF CML
WITH TKI
SESSION III
MPN RISK
STRATIFICATION
INCLUDING VASCULAR
EVENTS
DEBATE 1
INTERFERON ALPHA
SHOULD BE FRONT LINE
THERAPY IN ALL ET/PV
PATIENTS
ROUNDTABLE 1
INFECTIONS IN
MYELOPROLIFERATIVE
DISORDERS, INCLUDING
CML
ROUNDTABLE 2
PREGNANCY AND
PARENTING
DEBATE 2
ALLOGENEIC STEM CELL
TRANSPLANTATION
SHOULD BE CONSIDERED
THIRD LINE OPTION IN
CHRONIC PHASE CML
SESSION IV
EVOLVING THERAPIES
IN MYELOFIBROSIS
SESSION V
MANAGEMENT OF
ADVANCED AND UNUSUAL
DISEASE (MPN AND CML)
SESSION VI
TREATMENT FREE
REMISSION IN CML
KEYNOTE LECTURE
SELECTED ABSTRACTS
FOR AN ORAL
PRESENTATION
SELECTED ABSTRACTS
FO R A POSTER
PRESENTATION
DISCLOSURES